Business Description
Taisho Pharmaceutical Holdings Co Ltd
NAICS : 325412
SIC : 2834
ISIN : JP3442850008
Share Class Description:
TAISF: Ordinary SharesDescription
Taisho Pharmaceutical Holding Co Ltd is a specialty and generic drug manufacturing company. The company maintains two operational segments, Self-Medication and Prescription Pharmaceuticals. The vast majority of Taisho's revenue is derived from its Self-Medication segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The vast majority of sales are generated by sales to external customers in Japan.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.83 | |||||
| Interest Coverage | 87.55 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 4.59 | |||||
| Beneish M-Score | -2.6 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.5 | |||||
| 3-Year EBITDA Growth Rate | 4.1 | |||||
| 3-Year EPS without NRI Growth Rate | 5.4 | |||||
| 3-Year Book Growth Rate | 2.5 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 78.06 | |||||
| 9-Day RSI | 82.68 | |||||
| 14-Day RSI | 83.64 | |||||
| 6-1 Month Momentum % | 44.43 | |||||
| 12-1 Month Momentum % | 41.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.16 | |||||
| Quick Ratio | 4.37 | |||||
| Cash Ratio | 3.3 | |||||
| Days Inventory | 151.56 | |||||
| Days Sales Outstanding | 74.84 | |||||
| Days Payable | 42.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | -3.1 | |||||
| 3-Year Average Share Buyback Ratio | -0.9 | |||||
| Shareholder Yield % | 1.17 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 57.17 | |||||
| Operating Margin % | 5.9 | |||||
| Net Margin % | 2.63 | |||||
| FCF Margin % | -3.11 | |||||
| ROE % | 1.04 | |||||
| ROA % | 0.87 | |||||
| ROIC % | 1.81 | |||||
| ROC (Joel Greenblatt) % | 8.48 | |||||
| ROCE % | 1.93 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 99999999.99 | |||||
| PE Ratio without NRI | 99999999.99 | |||||
| Shiller PE Ratio | 99999999.99 | |||||
| PS Ratio | 59415826.91 | |||||
| PB Ratio | 22881546.79 | |||||
| Price-to-Tangible-Book | 32569334.04 | |||||
| Price-to-Operating-Cash-Flow | 99999999.99 | |||||
| EV-to-EBIT | 24.82 | |||||
| EV-to-Forward-EBIT | 11.53 | |||||
| EV-to-EBITDA | 24.82 | |||||
| EV-to-Forward-EBITDA | 4.4 | |||||
| EV-to-Revenue | 1.34 | |||||
| EV-to-Forward-Revenue | 0.67 | |||||
| EV-to-FCF | -45.64 | |||||
| Price-to-Projected-FCF | 23010023.01 | |||||
| Price-to-Median-PS-Value | 15.95 | |||||
| Price-to-Graham-Number | 44147137.17 | |||||
| Price-to-Net-Current-Asset-Value | 78204737.35 | |||||
| Price-to-Net-Cash | 99999999.99 | |||||
| Earnings Yield (Greenblatt) % | 4.03 | |||||
| FCF Yield % | -1.35 | |||||
| Forward Rate of Return (Yacktman) % | -6.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:TAISF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Taisho Pharmaceutical Holdings Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,260.176 | ||
| EPS (TTM) ($) | 19030149.126 | ||
| Beta | 0.35 | ||
| Volatility % | 54.34 | ||
| 14-Day RSI | 83.64 | ||
| 14-Day ATR ($) | 146443.43012 | ||
| 20-Day SMA ($) | 1594594594.5946 | ||
| 12-1 Month Momentum % | 41.76 | ||
| 52-Week Range ($) | 1027027027.027 - 1621755135.1351 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Taisho Pharmaceutical Holdings Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Taisho Pharmaceutical Holdings Co Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Taisho Pharmaceutical Holdings Co Ltd Frequently Asked Questions
What is Taisho Pharmaceutical Holdings Co Ltd(TAISF)'s stock price today?
The current price of TAISF is $1594594594.59. The 52 week high of TAISF is $1621755135.14 and 52 week low is $1027027027.03.
When is next earnings date of Taisho Pharmaceutical Holdings Co Ltd(TAISF)?
The next earnings date of Taisho Pharmaceutical Holdings Co Ltd(TAISF) is .
Does Taisho Pharmaceutical Holdings Co Ltd(TAISF) pay dividends? If so, how much?
Taisho Pharmaceutical Holdings Co Ltd(TAISF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers